Friday, October 07, 2016

1 comment:

Anonymous said...

New Anthem policy will cost DMD patients $300,000 or more

Anthem Inc. has made the striking decision not to cover Sarepta Therapeutics Inc.’s new $300,000-a-year Duchenne muscular dystrophy drug, citing the controversy around the treatment’s approval in its rationale.

Anthem’s new policy, the first announced by a health insurer, states that eteplirsen is “investigational and not medically necessary” because the drug’s effectiveness has not been proven.

The step is an unusual one for the nation’s second-largest health insurer to take, effectively questioning the validity of a much-disputed Food and Drug Administration approval in mid-September.

The new policy, made public by Anthem ANTM, -0.43% on Thursday, came as the drug was administered for the first time since approval to a 9-year-old from Jacksonville, Fla. with DMD.

Lack of insurance coverage should place a significant financial burden on those with DMD and their families. Sarepta said in late September that eteplirsen, also called Exondys51, will cost patients on average about $300,000 a year.

So what’s the FDA purpose again? They approved therapy yet Anthem disagrees?What a game with vulnerable lives...nice eh?